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Abstract
Introduction. Deficiency of folic acid (FA) has been identified as a risk factor for neural 
tube defects (NTDs) as well as other congenital anomalies. Thus, periconceptional folate 
supplementation is recommended for all women planning to get pregnant. 
Methods. We conducted a KAP (knowledge, attitude, practice) survey to investigate 
the use of FA and its appropriateness. The survey included a sample of 562 women who 
delivered in the Lazio region between 2013 and 2014. Two logistic regression analyses 
were performed to evaluate the association between the characteristics of participating 
women and both the information received on FA intake and its use. 
Results. The prevalence of periconceptional FA assumption was 19.4% although 82.2% 
of the interviewed women had planned their pregnancies. 
Conclusions. It shows that more periconceptional counseling is needed to increase 
women’s awareness on the opportunity of FA supplementation.
INTRODUCTION
Neural tube defects (NTDs) are severe congenital 
malformations with a prevalence between 0.2-10 cas-
es per 1000 established pregnancies worldwide, thus 
ranking among the most common birth defects [1]. 
So far, in Italy, only regional data is available on NTD 
prevalence, namely from the registries of congenital 
anomalies of two regions: Emilia Romagna and Tus-
cany. In these regions, total birth prevalence of NTDs 
are 0.53 and 0.56 per 1000 respectively [2]. NTD are 
thought to arise during the third and fourth week after 
fertilization [3], the period of the most rapid growth of 
the fetus and highest requirement of FA. Many studies 
showed that FA deficiency is a risk factor for NTDs and 
other congenital anomalies when there is a predispos-
ing genotype [4, 5]. Two randomized controlled trials 
[6, 7] on the efficacy of FA against NTDs have demon-
strated that FA taken before pregnancy reduces the in-
cidence of NTDs by 50-70% to a rate of approximately 
0.6 per 1000 pregnancies. However, many women of 
childbearing age seem not to be aware of the precon-
ceptional need of FA supplementation even in highly 
developed countries [8, 9]. Fortification of many cere-
al-grain foods became mandatory in the United States 
and in Canada already in 1998. This policy increased 
the average intake of FA among women of childbearing 
age by approximately 30 to 70% [10-12]. In Europe, 
national organizations have developed official guide-
lines [13]. The recommended approaches are different 
and include a number of strategies to reach red blood 
cell folate levels, providing the maximal protection 
from neural tube defects. The different recommenda-
tions depended on diet, ethnicity and genetic congeni-
tal anomaly risk status [14-16].
In 2004, the Italian Network for the promotion of FA 
intake [17] issued guidelines recommending FA supple-
mentation for 4 weeks prior to conception and through-
out the first trimester of pregnancy. 
In order to investigate the prevalence of FA utiliza-
tion and the information received on the proper peri-
conceptional use of this vitamin, we conducted the 
present study analyzing data of a sample of women who 
delivered in three birth centers of the Italian National 
Health Service (NHS) in the Lazio region. Out of the 
50 132 deliveries registered in the Lazio region in 2013, 
98.4% took place in public birth centers [18], whereas 
around 80% of Italian women are assisted antenatally 
by a private gynecologist [19].
METHODS
In the present study, data were extrapolated from a 
multicenter survey aimed at investigating drug use dur-
ing pregnancy [20]. The survey was conducted between 
2013 and 2014 at three Italian birth centers within the 
Lazio region, one located in a big city and two in small 
towns, namely San Giovanni Calabita Fatebene Fratelli 
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Hospital (FBF) in Rome; Santa Maria Goretti Hospi-
tal (SMG) in Latina; and Belcolle Hospital in Viterbo. 
The target population were women of all ages, either 
Italian citizens or foreigners, who delivered in a defined 
study period set to analyze 200 consecutive births in 
each center. The eligibility criteria were absence of se-
vere obstetric maternal complications and neonatal dis-
eases and knowledge of Italian language. Women with 
chronic disease and/or NTDs risk factors were includ-
ed. Representativeness of the sample has been investi-
gated by comparing socio-demographic characteristics 
of the sample with those of women who delivered in 
2013 in Italy [18]. Interviews were conducted by the 
use of a structured questionnaire, approved by the Ital-
ian National Institute of Health’s ethical board. The 
questionnaire was administered by trained interview-
ers at the maternal and childcare unit of each hospital. 
The interviews were held in a special room to provide 
privacy, ensuring confidentiality and anonymity; the 
average time of questionnaire administration was 20 
minutes. Each woman was asked to report about her so-
cio-demographic profile and if pregnancy was planned. 
Information on the FA dose, modality and duration of 
treatment were collected. Out-of-pocket costs of FA 
treatment for women who planned pregnancy were es-
timated. 
In order to investigate predictors of information re-
ceived on the proper FA intake, a logistic regression 
analysis was performed. The following independent 
variables were used: age classes (≤ 29, 30-34, ≥ 35); 
educational level (at least middle school graduation, 
high school graduation, university degree); profession 
(employed, unemployed or student, housewife), nation-
ality (Italian, foreign), parity, planned pregnancy, previ-
ous adverse outcomes (spontaneous abortion, ectopic 
pregnancy or stillbirth) and birth center. In addition, 
to investigate on the proper FA use, a second logistic 
regression analysis on women who planned pregnancy 
was performed using the same predictors. Both of the 
analysis were adjusted for the type of antenatal care re-
ceived during pregnancy (public or private).
Data were analyzed with the STATA/IC 11.0 version. 
RESULTS
Overall, 562 women (93.7%) were interviewed, with 
37 (6.2%) refusing to participate and one who could not 
be reached. 
Socio-demographic characteristics and obstetric 
history
Characteristics of participants are shown in Table 1: 
the mean age was 31.9 years (range 17-48), 32.0% of 
the sample was older than 35 years. The majority of 
women were married or cohabitant (93.3%) and Italian 
(86.8%). Overall, among foreigners the largest group 
was from Romania (13.2%). Around half of the women 
were primiparous and had a high level of education: 
81.6% had completed high school and among those 
35.9% had a university degree. Almost 70% of the sam-
ple was employed, and 17.9% were housewives. Most 
women received antenatal care from a private gynecolo-
gist (80.2%) and 82.2% had planned their pregnancies. 
Type of information on FA received either before 
or during pregnancy 
The percentage of interviewed women who received 
information on FA before or only during pregnancy 
was 42.0% and 46.3% respectively. Table 2 describes in 
detail the information offered to the women. Almost 
all women received information from the gynecologist, 
84.8% before and 97.6% during pregnancy. The General 
Practitioner (GP) informed only two women out of the 
total sample when none of women had been counseled 
by a midwife. 
The logistic regression (Table 3) showed that graduat-
ed women were more likely to be informed on the use of 
FA (ORadj 2.11; CI 95% 1.12-3.95) together with those 
women who had planned their pregnancy (ORadj 2.90; 
CI 95% 1.65-5.10) and with those who had a history 
of previous adverse obstetric outcomes (ORadj 1.81; 
CI 95% 1.12-2.92). Women who delivered at Belcolle 
Hospital were more informed (49.7%) on the correct 
FA consumption when compared to women from SMG 
Table 1
Socio-demographic characteristics and obstetric history of parti-
cipating women (N = 562)
Characteristics N %
Age
≤ 29 183 32.9
30-34 196 35.2
















Type of antenatal  
care 
private Gynaecologist 425 80.2
NHS Gynaecologist 73 13.8
FHC 32 6.0
Planned pregnancy  462 82.2







*spontaneous abortion, ectopic pregnancy or stillbirth.
NHS = National Health Service.
FHC = Family Health Centres.
FBF = Fatebenefratelli Hospital.
SMG = Santa Maria Goretti Hospital.
Belcolle = Belcolle Hospital.

























Information received on folic acid (FA) and periconceptional intake
  Before pregnancy Only during pregnancy
N % N %
Information received on FA 236 42.0 260 46.3
What is FA and its benefits 189 33.6 259 46.1
Recommended dosage 45 8.0 23 4.1
Recommended period of use 145 25.8 66 11.7
All pregnancy Planned pregnancy 
N % N %
Periconceptional FA intake 109 19.4 108 23.4
Table 3 
Predictor variables associated with FA information received before pregnancy (N = 562) and logistic regression* 
Variables   N % FA
informed
ORadj CI 95%
Interviewed women 562 42.0
Age      
≤ 29 183 32.8 1
30-34 196 43.9 1.22 0.74 2.00
≥ 35 178 49.4 1.40 0.85 2.31
Educational level
low 103 32.0 1
medium 257 36.6 1.12 0.65 1.94
high 202 54.0 2.11 1.12 3.95
Employment
employed 363 48.2 1
Student/ unemployed 92 28.3 0.64 0.36 1.12
housewife 99 29.3 0.57 0.32 1.02
Nationality
Italian 488 45.9 1
foreign 74 16.2 0.32 0.16 0.66
Parity
primiparous 302 41.7 1
multiparous 260 42.3 1.10 0.74 1.64
Planned pregnancy
No 100 21.0 1
Yes 462 46.5 2.90 1.65 5.10
History of adverse obstetric outcomes§
No 462 40.0 1
Yes 100 51.0 1.81 1.12 2.92
Birth centre
Belcolle 195 49.7 1.00
FBF 184 38.6 0.29 0.18 0.49
 SMG 183 37.2 0.53 0.33 0.85
*adjusted for type of antenatal care received during pregnancy (public or private).
§spontaneous abortion, ectopic pregnancy or stillbirth.
FA = Folic Acid.
ORadj = adjusted Odds Ratio.
CI = Confidence Interval.
FBF = Fatebenefratelli Hospital.
SMG = Santa Maria Goretti Hospital.
Belcolle = Belcolle Hospital.
























(OR 0.53; CI 95% 0.33-0.85) and from FBF (OR 0.29; 
CI 95% 0.18-0.49). Foreign women were less likely to 
be informed (adjusted OR 0.32, IC 95 % 0.16-0.66). 
The prevalence of recommended use
Overall, the prevalence of recommended use of FA 
was 19.4%. The majority of interviewed women started 
FA treatment only during pregnancy (74.9%); 5.1% of 
women never used FA. The use of periconceptional FA 
between primiparous was higher than among multipa-
rous (22.2% vs 16.2%). Recommended intake of FA was 
more common among women who planned pregnan-
cies than between those with unplanned pregnancies 
(23.4% vs 1.0%). 
Profile of women associated with the recommended 
intake of FA
Logistic regression analysis on data from women 
who planned pregnancies (N = 462; Table 4) showed 
that women aged 30-34 years were more likely to use 
periconceptional FA than those aged ≤ 29 (ORadj 2.00; 
CI 95% 1.03-3.88) as well as those with higher educa-
tion compared with the less educated (ORadj 3.44; CI 
95% 1.27-9.27). The probability to use FA properly was 
two times higher in women who had previous adverse 
pregnancy outcomes (ORadj 2.12; CI 95% 1.21-3.69) 
than those problem-free pregnancies. Also, women 
from FBF and SMG were less likely to use FA as rec-
ommended (ORadj 0.55 CI 95% 0.31-0.99; ORadj 0.49 
Table 4
Predictor variables associated with the recommended intake of FA in women who planned pregnancy (N = 462) and logistic regression*
Variables N % FA 
recommended 
ORadj CI 95%
Women who planned pregnancy 462 23.4
Age
≤ 29 140 13.6 1
30-34 163 29.5 2.00 1.03 3.88
≥ 35 155 25.8 1.63 0.83 3.19
Educational level
low 75 9.3 1
medium 207 19.8 2.02 0.78 5.27
high 179 34.1 3.44 1.27 9.27
Employment
employed 314 29.0 1
student/unemployed 78 9.0 0.73 0.33 1.61
housewife 62 14.5 0.39 0.16 0.96
Nationality
Italian 413 25.2 1
foreign 48 10.4 0.51 0.18 1.50
Parity
primiparous 255 26.7 1
multiparous 206 19.9 0.65 0.40 1.06
History of adverse obstetric outcomes§
no 343 18.9 1
yes 116 37.9 2.12 1.21 3.69
Birth centre
Belcolle 156 25.0 1.00
FBF 166 27.7 0.55 0.31 0.99
 SMG 139 17.3 0.49 0.26 0.92
*adjusted for type of antenatal care received during pregnancy (public or private).
§ spontaneous abortion, ectopic pregnancy or stillbirth.
FA = Folic Acid.
ORadj = adjusted Odds Ratio.
CI = Confidence Interval.
FBF = Fatebenefratelli Hospital.
SMG = Santa Maria Goretti Hospital.
Belcolle = Belcolle Hospital.
























CI 95% 0.26-0.92) compared with Belcolle Hospital. 
Finally, housewives were less likely to use FA with the 
recommended intake than employed women (adjusted 
ORadj 0.39; CI 95% 0.16-0.96).
Dosage and duration of FA treatment 
The majority (76.0%) started the treatment only dur-
ing the first trimester of pregnancy. Around 80% contin-
ued the treatment throughout pregnancy and only three 
women out of 562 assumed FA no longer than required 
(i.e., first trimester). During pregnancy 47.2% took 0.4 
mg per day and 45.4% more than 0.4 mg per day. In our 
sample none reported a previous NTD and the number 
of women with important risk factors for this condition 
is very low. Three women were in treatment with anti-
epileptic drugs and 2 were affected by diabetes, all of 
them took 0.4 mg of FA. 
Cost of FA treatment 
The average out-of-pocket cost estimate of FA was 
0.32 € per tablet. FA treatment costs were different de-
pending on the duration and on the type of product. To 
calculate the average cost for each woman we divided 
women into two groups: 1) women who had taken FA 
antenatally and during pregnancy; 2) women who had 
taken FA only during pregnancy. Costs of FA treatment 
were on average 147 € (range 16-525 €) per group I and 
106 € (range 15-441 €) per group II.
DISCUSSION
The present study provides an up-to-date insight on 
recommended FA intake among women giving birth 
in the Lazio region. We were interested in evaluating 
the women’s awareness and actual use of FA. Although 
FA is obtainable free of charge through the NHS on 
prescription, this vitamin can also be purchased as an 
over-the-counter drug in Italy. The KAP survey was an 
essential tool in order to assess the actual consumption 
of FA because its use can only be partially electronically 
monitored.
Despite several initiatives that have been undertaken 
at national level [21, 22], preconceptional counsel-
ling offer is still low among health professionals. Only 
42.0% of the interviewed women received proper coun-
seling on FA preconceptional supplementation. Only 
33.6% received antenatal information on its benefits 
and only 25.8% on the importance to take it at least 
one month before conception and in the first three 
months of pregnancy. A previous study performed in 
Italy [19] stressed the importance of family health cen-
ters (FHC) in periconceptional care and counselling. 
Since FHC are multidisciplinary/integrated services, 
they interact with young women on a regular or sched-
uled basis. These services might provide an ideal op-
portunity to share information regarding FA benefits. 
A survey conducted in Spain concluded that the in-
formation provided in primary care about periconcep-
tional FA intake is crucial to promote its use during the 
protective period [9]. In our survey almost all women 
who had been informed received information from the 
gynecologist. This result is consistent with the fact that 
almost all Italian women are assisted antenatally by a 
gynecologist [19]. Nevertheless GPs as well as mid-
wives should be more involved in offering proactive 
preconceptional counseling on FA supplementation. 
We observed that women who delivered at Belcolle 
Hospital were more informed (49.7%) on the correct 
FA intake when compared to women from SMG and 
from FBF. Despite lack of information in order to de-
tect the underlying reasons, this observation highlights 
an improvement opportunity. 
Previous similar Italian surveys showed an increase 
in the intake of FA starting from 2004 when the na-
tional guidelines [17] were released and the Italian 
Network for the promotion of FA implemented its ac-
tivities [23]. The FA periconceptional intake reached 
values between 21%-38% in the years 2008-2012 [19, 
24-26]. Differences in rates observed in the mentioned 
studies were likely due to the different methodological 
approaches. 
Although the preventive effect of FA has been dem-
onstrated [6, 7], our study showed that these numbers 
did not improve further and highlighted that the recom-
mended FA intake remained low (19.4%) even though 
82.2% of participants planned their pregnancies. Well-
educated women were more acknowledgeable on the 
necessity of FA intake. The higher educational degree 
of the interviewed women (35.9%) compared to those 
who delivered in Italy (25.9%) [18] could therefore only 
improve adherence to proper FA consumption. 
This underlines the importance of providing appropri-
ate counselling especially to women in disadvantaged 
socioeconomic conditions. Moreover, communication 
problems could partially explain why foreign women 
were less likely to take FA properly. Together, this infor-
mation suggests that a more active role of health profes-
sionals is necessary in order to increase the overall FA 
use and to reduce social disparities. 
Primiparous were more likely to take FA as compared 
with multiparous (22.2% vs 16.2%). Probably because 
the importance of appropriate FA intake was not ex-
plained by health professionals even before subsequent 
pregnancies. Alternatively, women with healthy chil-
dren may have become less sensitive to the issue. 
A considerable number of women (17.5%) had a lon-
ger and a higher FA intake than recommended (more 
than 0.4 mg per day) probably because only 8% received 
an appropriate counselling on FA dosage antenatally 
and 13.7% during pregnancy. Given the small number 
of women with risk factors for NTDs, we are confident 
that the proportion of women taking a high-dose of FA 
supplementation is not biased and that almost half of 
the sample took an inappropriate dosage of FA.
Other surveys implemented in Italy [19, 26] confirm 
the same risk factors detected in our study: multipa-
rous, foreigners and less educated women are at higher 
risk of not taking FA as recommended. As reported in a 
French survey [27] also in the present study the likeli-
hood of proper FA use was three times higher in women 
who had pregnancy complications in the past. Poten-
tially health professionals were more prone to inform 
these patients. Alternatively, these women were more 
demanding in receiving advice or were more willing to 
follow preventative recommendations.
























Finally, an estimate of the FA treatment cost per 
woman was calculated. Some women took the vitamin 
alone whereas others consumed it in combination with 
multivitamin supplements. Since these supplements 
are more expensive and not reimbursed by NHS, they 
constitute an extra cost. As additional vitamins provide 
no documented further benefit during uncomplicated 
pregnancy [28, 29] avoiding multivitamin supplements 
could be an opportunity to reduce out of pocket ex-
penses. The cost of FA intake was also dependent on 
the duration of treatment and on the type of product 
with an estimate ranging from 16 € to 525 €. Since the 
Italian NHS covers the cost of the therapy, the price is 
not a true obstacle for the FA intake. However, women 
should also be informed of the gratuitousness of FA. 
We conclude that more information and promotion 
of appropriate FA consumption from institutions and 
health professionals is required in order to inform wom-
en on the guidelines of FA intake and on its free avail-
ability. For this reason we setup a website offering sever-
al information regarding FA (www.epicentro.iss.it/temi/
materno/consumo_farmaci_gravidanza/index.html).
Limitations of the present study include the region-
specific nature of data. This factor limits the strength 
and the external validity of the conclusions of this 
study. Therefore, further studies involving women from 
a broader geographic distribution will help to provide 
more representative results.
CONCLUSIONS
In Italy, the intake of periconceptional FA is incentiv-
ized: when prescribed, the expenses are reimbursed by 
the NHS. However, our survey shows that only 19.4% 
of women follow the FA periconceptional supplemen-
tation national guidelines. Young women, foreigners, 
housewives and women with lower educational level are 
less likely to take FA appropriately before and during 
pregnancy. Therefore, health providers and institutions 
are challenged to offer better counseling and informa-
tion on FA periconceptional supplementation. FHCs, 
physicians (both gynecologists and GP) as well as mid-
wives should have a greater proactive role in preconcep-
tional counseling. 
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